BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AGB101 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AGB101\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05824728-716@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AGB101: Phase 2 readout est. (NCT05824728)
DESCRIPTION:AGB101\, phase 2.\nStudy: Clinical Trial Evaluating the Efficac
 y and Safety of AGB101 for Treatment of Parkinson's Disease Related Psycho
 sis\nEstimated primary completion: December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/agb101#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05824728
URL:https://assetmemo.bio/drug/agb101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06919926-716@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:AGB101: Phase 2 readout est. (NCT06919926)
DESCRIPTION:AGB101\, phase 2.\nStudy: Clinical Trial Evaluating the Efficac
 y of AGB101 for Reducing Hippocampal Overactivity in Older Adults\nEstimat
 ed primary completion: May 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/agb101#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06919926
URL:https://assetmemo.bio/drug/agb101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
